A Multi-Centre, Randomised, Double-Blind, Cross-Over Design Study to Evaluate Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) 320/9microg One Inhalation Twice Daily Compared With Placebo and Oxis [formoterol] 9microg One Inhalation Twice Daily in Patients With Severe COPD [chronic obstructive pulmonary disease]
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Budesonide/formoterol (Primary) ; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 05 Aug 2010 Primary endpoint results (n=111) published in Respiratory Medicine
- 05 Oct 2008 Actual patient number (137) added as reported by ClinicalTrials.gov.
- 05 Oct 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov